CGA gene (coding for the α subunit of glycoprotein hormones) overexpression in ERα-positive prostate tumors

European Urology

Volumn 41, Issue 3, 2002, Pages 335-341

  Bièche, Ivan ^a,b   Latil, Alain ^c   Parfait, Béatrice ^a   Vidaud, Dominique ^a   Laurendeau, Ingrid ^a   Lidereau, Rosette ^b   Cussenot, Olivier ^c   Vidaud, Michel ^a  

^a FACULTÉ DES SCIENCES PHARMACEUTIQUES ET BIOLOGIQUES   (France)

^b CENTRE RENÉ HUGUENIN   (France)

^c Parc Scientifique de Luminy   (France)

Author keywords

CGA; ER ; Prostate cancer; Real time RT PCR quantification

Indexed keywords

ANDROGEN RECEPTOR; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; MESSENGER RNA;

ALPHA CHAIN; ARTICLE; BREAST CANCER; CANCER CELL; CARCINOGENESIS; CLINICAL ARTICLE; FOLLICLE STIMULATING HORMONE BETA SUBUNIT GENE; GENE; GENE OVEREXPRESSION; HUMAN; HUMAN CHORIONIC GONADOTROPIN ALPHA SUBUNIT GENE; HUMAN CHORIONIC GONADOTROPIN BETA SUBUNIT GENE; HUMAN TISSUE; LUTEINIZING HORMONE BETA SUBUNIT GENE; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROSTATE TUMOR; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THYROID STIMULATING HORMONE BETA SUBUNIT GENE;

BREAST NEOPLASMS; FEMALE; GENE EXPRESSION; GLYCOPROTEINS; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, ESTROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 0036522580     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0302-2838(02)00020-9     Document Type: Article

References (27)

1. Bièche I, Parfait B, Le Doussal V, Olivi M, Rio M-C, Lidereau R. et al. Identification of CGA as a novel estrogen receptor-responsive gene in breast cancer: An outstanding candidate marker to predict the response to endocrine therapy. Cancer Res 2001;61:1652-8.
2. Henderson BE, Feigelson HS. Hormonal carcinogenesis. Carcinogenesis 2000;21:427-33.
3. Mobbs BG, Johnson IE, Liu Y. Quantitation of cytosolic and nuclear estrogen and progesterone receptor in benign, untreated, and treated malignant human prostatic tissue by radioligand binding and enzyme-immunoassays. Prostate 1990;16:235-44.
4. Brolin J, Skoog L, Ekman P. Immunohistochemistry and biochemistry in detection of androgen, progesterone, and estrogen receptors in benign and malignant human prostatc tissue. Prostate 1992;20:281-95.
5. Castagnetta LA, Carruba G. Metastatic lesions from prostate cancer do not express oestrogen and progesterone receptors. J Pathol 1998;185:435-7.
6. Hobisch A, Hittmair A, Daxenbichler G, Wille S, Radmayr C, Hobisch-Hagen P, et al. Metastatic lesions from prostate cancer do not express oestrogen and progesterone receptors. J Pathol 1997;182:356-61.
7. Bonkhoff H, Fixemer T, Hunsicker I, Remberger K. Estrogen receptor expression in premalignant prostatic lesions. Am J Pathol 1999;155:641-7.
8. Mellinger GT, Gleason D, Bailar III J. The histology and prognosis of prostatic cancer. J Urol 1967;97:331-7.
9. Schroder FH, Hermanek P, Denis L, Fair WR, Gospodarowicz MK, Pavone-Macaluso M. The TNM classification of prostate cancer. Prostate Suppl 1992;4:129-38.
10. Latil A, Bièche I, Vidaud D, Lidereau R, Berthon P. Cussenot O, et al. Evaluation of androgen (AR), estrogen (ERα and ERβ) and progesterone (PGR) receptor expression in human prostate cancer by real-time quantitative reverse transcription PCR assays. Cancer Res 2001;61:1919-26.
11. Bellet D, Lazar D, Bièche I, Paradis V, Giovangrandi Y, Paterlini P, et al. Malignant transformation of nontrophoblastic cells is associated with the expression of chorionic gonadotropin β genes normally transcribed in trophoblastic cells. Cancer Res 1997;57:516-23.
12. Gibson UEM, Heid CA, Williams PM. A novel method for real-time quantitative RT-PCR. Genome Res 1996;6:995-1001.
13. Dirnhofer S, Berger C, Hermann M, Steiner G, Madersbacher S, Berger P. Coexpression of gonadotropic hormones and their corresponding FSH- and LH/CG-receptors in the human prostate. Prostate 1998;35:212-20.
14. Di San' Agnese PA. Euroendocrine differentiation in human prostatic carcinoma. Hum Pathol 1992;23:287-96.
15. Abrahamsson PA, Lilja H. Partial characterization of a thyroid-stimulating hormone-like peptide in neuroendocrine cells of the human prostate gland. Prostate 1989;14:71-81.
16. Bostwick DG, Dousa MK, Crawford BG, Wollen PC. Neuroendocrine differentiation in prostatic intraepithelial neoplasia and adenocarcinoma. Am J Surg Pahol 1994;18:1240-6.
17. Di San' Agnese PA, Cockett AT. The prostatic endocrine-paracrine (neuroendocrine) regulatory system and neuroendocrine differentiation in prostatic carcinoma: A review and future directions in basic research. J Urol 1994;152:1927-31.
18. Cussenot O, Villette JM, Valeri A, Cariou G, Desgrandchamps F, Cortesse A, et al. Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma. J Urol 1996;155:1340-3.
19. Cussenot O, Villette JM, Cochand-Priollet B, Berthon P. Evaluation and clinical value of neuroendocrine differentiation in human prostatic tumors. Prostate 1998;8:43-51.
20. Konishi N, Nakaoka S, Hiasa Y, Kitahori Y, Ohshima M, Samma S. Immunohistochemical evaluation of estrogen receptor status in benign prostatic hypertrophy and in prostate carcinoma and the relationship to endocrine therapy. Oncology 1993;50:259-63.
21. Nativ O, Umehara T, Colvard DS, Therneau TM, Farrow GM, Spelsberg TC, et al. Relationship between DNA Ploidy and functional estrogen receptors in operable prostate cancer. Eur Urol 1997;32:96-9.
22. Lau K-M, LaSpina M, Long J, Ho S-M. Expression of estrogen receptor ERα and ERβ in normal and malignant prostatic epithelial cells: Regulation by methylation and involvement in growth regulation. Cancer Res 2000;60:3175-82.
23. Li L-C, Chui R, Nakajima K, Oh BR, Au HC, Dahiya R. Frequent methylation of estrogen receptor in prostate cancer: Correlation with tumor progression. Cancer Res 2000;60:702-6.
24. Glick JH, Wein A, Padavic K, Negendank W, Harris D, Brodovsky H. Phase II trial of tamoxifen in metastatic carcinoma of the prostate. Cancer 1982;49:1367-72.
25. Spremulli E, DeSimone P, Durant J. A phase II study of nolvadex tamoxifen citrate in the treatment of advanced prostatic adenocarcinoma. Am J Clin Oncol 1982;5:149-53.
26. Horton J, Rosenbaum C, Cummings FJ. Tamoxifen in advanced prostate cancer: An ECOG pilot study. Prostate 1988;12:173-7.
27. Bergan RC, Reed E, Myers CE, Headlee D, Brwley O, Cho H-K, et al. A phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer. Clin Cancer Res 1999;5:2366-73.